Arthritis Rheum 1998; 41: 754Alsalameh S, Manger B et al (1998) New onset of rheumatoid arthritis during interferon beta-1B treatment in a patient with multiple sclerosis: comment on the case report by Jabaily and Thompson. Arthritis Rheum 41(4):754...
“When an arthritis patient walks in the front door, I feel like leaving by the back door.” At the beginning of my training, it was not uncommon to see numerous assistive devices in the waiting room of the department as the hospital was full of patients ...
This article synthesizes information from studies on recent advances in the management of rheumatoid arthritis outlining diagnosis and assessment, disability issues, outcome studies, current status of traditional and experimental pharmacological therapies, and new strategies of nonpharmacological treatments aimed...
Thirty-four patients with rheumatoid arthritis (RA) were treated with a new agent (ICI 55 897) in addition to basic therapy with nonsteroid anti-inflammatory drugs. Five patients had the drug for less than 28 days; the remaining 29 were observed for periods up to a year. At 140 days, ...
Rheumatoid Arthritis--Update on New Therapies. Presents information on primary care therapies for rheumatoid arthritis (RA). Description of the disease; Drug choices for RA; Effectiveness of traditional... Mclain,A David - 《Southern Medical Journal》 被引量: 4发表: 2001年 ...
Baricitinib is a type of drug known as a Janus kinase (JAK) inhibitor and is usually used to treat rheumatoid arthritis. The researchers say another arthritis drug, interleukin-6 (IL-6), could also be used to treat COVID-19, however, trials of two other JAK inhibitors, ruxolitinib and to...
or that affect more than 5 in 10,000 persons but where it is unlikely that expected sales of the product would cover the investment in its development. More information about the qualifying criteria, features, and incentives involved in an orphan drug designation can be found on the EMA’s ...
At ARBDA, we encourage you to attend regular evaluations with a rheumatologist. Utilizing advanced diagnostic tools, we can identify autoimmune disease markers early on. The two primary forms of arthritis,rheumatoid arthritisandosteoarthritis, affect the body in different ways — but share a commonalit...
Advances in Biologic Agents for the Treatment of Rheumatoid Arthritis. TNF-.. (infliximab, etanercept, adalimumab), IL-1 (anakinra) and IL-6 (tocilizumab) inhibitors, a B-cell depleting agent (rituximab) and a drug ... Gur,Ali,Oktayoglu,... - 《Anti Inflammatory & Anti Allergy Agents in...
Some third parties are outside of the European Economic Area, with varying standards of data protection. See our privacy policy for more information on the use of your personal data. Manage preferences for further information and to change your choices. Accept all cookies ...